All Newborns To Be Screened For SMA

Families affected by spinal muscular atrophy (SMA) have welcomed a significant breakthrough after the announcement that all newborn babies in England will be offered screening for the condition as part of a major national study.

The decision marks an important moment for the SMA community, with campaigners, healthcare professionals and families celebrating the potential to change lives through earlier diagnosis and treatment.

Why Early Diagnosis Matters

Spinal muscular atrophy is a rare inherited condition that causes progressive muscle weakness. It can affect a child’s ability to move, swallow and breathe, and in its most severe forms can be life-limiting during early childhood.

One of the biggest challenges with SMA has always been timing. While revolutionary gene therapies and other treatments are now available, they work best before symptoms appear. Once nerve cells have been damaged, treatment cannot reverse that damage.

By introducing newborn screening, babies with SMA can be identified within days of birth, giving doctors the opportunity to begin treatment as early as possible. For many children, this could mean a healthier future with improved mobility, independence and quality of life.

Jesy Nelson’s Campaign

Former Little Mix singer Jesy Nelson has become one of the most recognisable voices campaigning for newborn SMA screening after her twin daughters, Ocean Jade and Story Monroe Nelson-Foster, were diagnosed with the condition.

Sharing the emotional reality of her family’s journey, Nelson has spoken openly about being told her daughters might never walk and about the daily challenges they face, including wearing spinal jackets and foot splints.

Following the government’s announcement, she described the decision as “a victory for every family” affected by SMA.

Although the screening programme cannot change the diagnosis of children already living with the condition, it offers hope that future families will receive answers sooner and have access to life-changing treatment before symptoms develop.

What the New Programme Means

The screening will be introduced across most of England from October 2026, with nationwide expansion expected by October 2027.

The simple heel-prick blood test will be added to existing newborn screening and will involve hundreds of thousands of babies. Researchers at the University of Oxford will lead the study, providing evidence to help determine whether SMA screening should become a permanent part of the UK’s newborn screening programme.

Scotland already screens newborns for SMA, and many families hope England’s programme will soon become a permanent nationwide service.

A Victory for Families and Campaigners

This announcement highlights the incredible impact that patient advocacy and public awareness can have on healthcare policy.

Families living with rare conditions often spend months or even years fighting for recognition, diagnosis and access to treatment. The voices of campaigners, charities, clinicians and parents have helped ensure that newborn screening for SMA has become a national priority.

For many, this represents more than a medical advancement—it is a recognition that every child deserves the best possible start in life.

Looking Ahead

The introduction of newborn SMA screening is a powerful reminder of how advances in genetic medicine are transforming healthcare.

While there is still much work to be done to improve support for people living with SMA and other rare conditions, earlier diagnosis offers families something invaluable: time.

Time to begin treatment.

Time to prepare.

And, most importantly, time to give children the greatest possible opportunity to thrive.

For families affected by SMA, this announcement is not just a policy change—it is a beacon of hope for future generations.